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The extrahypothalamic growth hormone-releasing hormone (GHRH)
and its cognate receptors (GHRH-Rs) and splice variants are expressed
in a variety of cancers. It has been shown that the pituitary type of
GHRH-R (pGHRH-R) mediates the inhibition of tumor growth in-
duced by GHRH-R antagonists. However, GHRH-R antagonists can
also suppress some cancers that do not express pGHRH-R, yet the
underlying mechanisms have not been determined. Here, using
human esophageal squamous cell carcinoma (ESCC) as a model, we
were able to reveal that SV1, a known splice variant of GHRH-R, is
responsible for the inhibition induced by GHRH-R antagonist MIA-
602. We demonstrated that GHRH-R splice variant 1 (SV1) is a
hypoxia-driven promoter of tumor progression. Hypoxia-elevated
SV1 activates a key glycolytic enzyme, muscle-type phosphofructo-
kinase (PFKM), through the nuclear factor kappa B (NF-κB) pathway,
which enhances glycolytic metabolism and promotes progression of
ESCC. The malignant actions induced by the SV1–NF-κB–PFKM path-
way could be reversed by MIA-602. Altogether, our studies demon-
strate a mechanism by which GHRH-R antagonists target SV1. Our
findings suggest that SV1 is a hypoxia-induced oncogenic promoter
which can be an alternative target of GHRH-R antagonists.
splicing isoform of GHRH-R | GHRH-R antagonist | PFKM | glycolysis |
hypoxia
Aberrant RNA splicing is a common characteristic of cancers(1–3). Products of alternative splicing may display functions
distinct from their canonical full-length transcripts, tending to
mediate constitutively active proto-oncogenes, regulating cancer
stem cells, promoting metastasis, and developing resistance to
therapy (4–6). Emerging evidence strongly suggests that hypoxia
is a key driver of alternative splicing in cancers (7). However,
splice variants that occur during hypoxia and their roles in on-
cogenesis are much less understood.
A stimulatory loop formed by tumor-derived growth hormone-
releasing hormone (GHRH) and its receptors has been shown to
promote the growth of many cancers, which can be blocked by
antagonists of GHRH’s cognate receptor (GHRH-R) (8–10). Thus,
the pituitary-type GHRH receptor (pGHRH-R), a canonical full-
length transcript, has been detected in many human neoplastic cells
and tissues, mediating the antiproliferative effects of GHRH-R
antagonists (8, 9, 11–14). However, the underlying mechanisms of
the antitumor activities of GHRH-R antagonists are far from being
elucidated. For example, GHRH-R antagonists exhibit antitumor
effects in the subgroup of cancers that do not harbor GHRH-R
overexpression, such as ovarian cancer, pancreatic cancer, and
melanoma (15–17), suggesting that there may be alternative
targets responding to these antagonists. The splice variant type
1 (SV1) of GHRH-R was detected in human cancers in the
laboratory of one of us (A.V.S.) (18) and was demonstrated to
possess ligand-dependent as well as ligand-independent activity
(19). SV1 was enriched in extrapituitary neoplastic tissues (20).
However, the functional role of SV1 in human malignancies is
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largely unknown. Moreover, it remains to be clarified whether
SV1 acts as an alternative target of GHRH-R antagonists in a
subgroup of cancers that express barely detectable levels of
GHRH-R but high levels of SV1.
In this study, we showed that SV1 was induced by hypoxia in
esophageal squamous cell carcinoma (ESCC), which barely
harbors GHRH-R overexpression. Using cellular and animal
studies, we detected an unappreciated hypoxia-SV1-inflammation-
metabolic signaling in ESCC, providing evidence for the func-
tionality of GHRH-R antagonists in a pattern common in all
cancers.
Results
GHRH-R Splice Variant SV1 Mediates the Inhibitory Effect of GHRH-R
Antagonist MIA-602 in Human ESCC. GHRH-R antagonists can in-
hibit the proliferation of a variety of human malignancies, some
of which express low levels of GHRH-R (15, 21). It was claimed
that the GHRH-R protein was barely detectable in human esoph-
ageal cancer (22). To investigate whether GHRH-R antagonists
have inhibitory effects on human ESCC, ESCC cells KYSE150 and
HKESC-2 were treated with different concentrations of MIA-602
for 48 h. MIA-602 began to exert significant inhibitory effects on
cell viability at 5 μM in both cells (P < 0.01 for 5 μM, and P < 0.001
for 10 μM) (Fig. 1A and SI Appendix, Fig. S1A). Subsequently, a
real-time cell analyzer (RTCA) was used to investigate the dy-
namic behavior of migration and invasion of KYSE150 cells ex-
posed to MIA-602 (SI Appendix, Fig. S1 B and C). We found that
cell migration and invasion were both significantly inhibited by
MIA-602 treatment, compared to KYSE150 cells treated with the
vehicle solution. To explain these results, we examined the ex-
pression of pGHRH-R, the known target of GHRH-R antago-
nists, in a panel of human ESCC cells, as well as two immortalized
esophageal epithelial cells (NE2 and NE083) as normal controls.
Nearly all these cells expressed very low pGHRH-R (SI Appendix,
Fig. S1D), indicating that pGHRH-R is probably not the target of
GHRH-R antagonists in ESCC. One of the splice variants of
GHRH-R, SV1, was reported to be highly expressed in several
types of cancer (23). Therefore, we determined the mRNA
level for SV1 in these cells. SV1 had relatively high expression
in ESCC cells, especially in HKESC-2 cells, whereas the normal
cells, NE2 and NE083, expressed relatively low levels of SV1 (SI
Appendix, Fig. S1D). Immunoblotting analysis further confirmed
that the protein level for SV1 was higher than that of pGHRH-R
in TE1, KYSE140, HKESC-2, and KYSE150 cells, with a more
enriched pattern in HKESC-2 and KYSE150 cells (Fig. 1B).
We compared the levels of pGHRH-R and SV1 in 58 human
primary ESCCs, and the results showed that SV1 was more
abundant in tumors than pGHRH-R (P < 0.0001) (Fig. 1C).
Moreover, a comparison between tumor and adjacent nontumor
tissues revealed insignificant levels of pGHRH-R, while SV1 was
significantly higher in tumor tissues (P < 0.01 for Fig. 1E) (Fig. 1
D and E). Receiver operator characteristic (ROC) analysis
identified an optimal cutoff score of 0.012 for RT-qPCR, which
categorized 48.28% (28 of 58) for overexpression of SV1 (SI
Appendix, Fig. S1E). SV1 expression was positively correlated
with the largest tumor dimension (P = 0.006), pathological nodal
(pN) status (P = 0.004), and pathological stage of tumor nodal
metastasis (pTNM) (P = 0.034), as indicated by correlation assay
(SI Appendix, Table S1), supporting that SV1 is highly expressed
in human ESCC and is closely associated with disease progres-
sion. Furthermore, Kaplan‒Meier survival analysis revealed a
shorter overall survival (OS) for ESCC patients with increasing
expression of SV1 (log-rank test, P < 0.001) (Fig. 1F). the multi-
variate Cox regression model showed that SV1 expression is an
independent prognostic factor for patients with ESCC [hazard
ratio (HR) = 4.269, 95% CI = 1.547–11.775, P = 0.005] (SI
Fig. 1. MIA-602 inhibits ESCC cell progression through SV1. (A) Viability of KYSE150 cells treated with MIA-602 (0.1, 1, 5, or 10 μM) or vehicle solution for 48 h
measured by cell-counting kit 8 (CCK-8) assay. (B) Protein levels of pGHRH-R and SV1 in four ESCC cells. GAPDHwas used as an internal control. (C) RT-qPCR analyses
of pGHRH-R and SV1 in 58 human ESCC specimens. (D and E) RT-qPCR analyses of pGHRH-R (D) and SV1 (E) in 20 human ESCC tissues and paired adjacent
noncancerous tissues. (F) Kaplan–Meier analysis showing that OS was significantly better in patients with low expression of SV1 than in those with high expression.
(G) KYSE150 cells treated with MIA-602 or vehicle; levels of SV1 were determined by RT-qPCR. (H) Proliferation of SV1-overexpressing KYSE140 cells monitored by
the xCELLigence RTCA dual-plate (DP) system (ACEA Biosciences). Quantitative analysis of the cell index at 60 h is shown. (I) Viability of SV1-overexpressing
KYSE150 cells treated with MIA-602 or vehicle measured by CCK-8 assay. (J) Proliferation of SV1-knockdown KYSE150 cells monitored by the xCELLigence RTCA DP
system. Quantitative analysis of the cell index at 60 h is shown. Error bars indicate SEM. N.S., not significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by
one-way ANOVA with post hoc intergroup comparisons (A, I, and J) or student’s t test (C–E, G, and H); n = 3 in each group (A, G, and I).







































Appendix, Table S2). Survival and multivariate analyses confirmed
the clinical relevance of SV1 as a prognostic marker for OS in
patients with ESCC.
Notably, administration of MIA-602 decreased expression of
SV1 in KYSE150 and HKESC-2 cells (P < 0.001) (Fig. 1G and SI
Appendix, Fig. S1F). These data suggest that SV1 is a potential
intrinsic oncogene and a target for GHRH-R antagonists in
ESCC. We then stably overexpressed SV1 in TE1 and KYSE140
cells to assess the role of SV1 (P < 0.001) (SI Appendix, Fig. S1
G–J). Cell proliferation monitored by real-time cell analyzer
(RTCA) showed that overexpression of SV1 resulted in signifi-
cantly enhanced cell proliferation in both cells, compared with
the vector control cells, respectively (P < 0.001 for Fig. 1H; P <
0.01 for SI Appendix, Fig. S1K) (Fig. 1H and SI Appendix, Fig.
S1K). Moreover, the overexpression of SV1 successfully reversed
the decrease in cell viability induced by MIA-602 in KYSE150
cells (Fig. 1I and SI Appendix, Fig. S1 L and M). To confirm
whether SV1 mediates the inhibitory effect of MIA-602, low SV1
expressors (TE1 and KYSE140) were treated with different
concentrations of MIA-602 and subjected to cell viability assay.
We found that MIA-602 did not exert significant inhibitory ef-
fects until the concentration reached 10 μM in both cells (P <
0.05 for 10 μM in KYSE140 cells, and P < 0.01 for 10 μM in TE1
cells) (SI Appendix, Fig. S2 A and B), which was higher than the
concentration of 5 μM MIA-602 required in high SV1 expressors
(KYSE150 and HKESC-2) (Fig. 1A and SI Appendix, Fig. S1A).
However, inhibition of viability was observed in KYSE140 cells
overexpressing SV1 with as little as 1 μM MIA-602 (P < 0.01 for
1 and 2.5 μM, and P < 0.001 for 5 μM in KYSE140-SV1 cells) (SI
Appendix, Fig. S2C). In addition, results from colony formation
assay showed that a concentration of 2.5 μM MIA-602 could
significantly reduce the number of colonies of KYSE150 cells but
not that of KYSE140 cells (P < 0.05 for 1 μM in KYSE150 cells
and 5 μM in KYSE140 cells; P < 0.01 for 2.5 and 5 μM in
KYSE150 cells) (SI Appendix, Fig. S2D). Furthermore, stable
KYSE150 cells expressing SV1 shRNA were established for
detecting the role of SV1 with or without MIA-602 treatment
(P < 0.001 for SI Appendix, Fig. S2E) (SI Appendix, Fig. S2 E and
F). Cell proliferation monitored by RTCA showed that knock-
down of SV1 decreased cell proliferation in KYSE150 cells (P <
0.01) (Fig. 1J). MIA-602 did not exert significant inhibitory ef-
fects even when the concentration reached 5 μM in SV1-
knockdown KYSE150 cells (SI Appendix, Fig. S2G). Collec-
tively, these results confirm that SV1 was the target of the
GHRH-R antagonist MIA-602 and was able to mediate MIA-
602’s inhibitory effects in human ESCC.
SV1 Induced by Hypoxia Contributes to Aberrant Glycolysis. Re-
cently, hypoxia within tumor tissues was indicated as a driver of
alternative splicing that contributes to tumorigenic development
(24). To test the hypothesis that hypoxia in ESCC leads to al-
ternative splicing of pGHRH-R into SV1, we examined the
transcript of SV1 on ESCC cells grown under normoxia and
hypoxia. A significant increase in SV1 expression was seen in
KYSE140 and TE1 cells grown under hypoxia (P < 0.0001 for
both) (Fig. 2A and SI Appendix, Fig. S3A). This finding supports
the speculation that hypoxia induces elevation of SV1 through
driving the alternative splicing of GHRH-R (Fig. 2B). Hypoxic
cancer cells are often forced into aberrantly increased glycolysis
(25). We observed significantly higher lactate production and
glucose uptake in ESCC cells under hypoxia, compared with cells
grown under normoxia (SI Appendix, Fig. S3 B and C). Results
from gene set enrichment analysis (GSEA) using microarray
dataset GSE47404 showed that the levels of mRNA for SV1
significantly correlated with the glycolytic pathways in ESCC
(P = 0.035) (Fig. 2C). These results suggest that SV1 was in-
duced by hypoxia and resulted in promotion of glycolysis in
ESCC. To validate whether GHRH-R antagonists could
interfere with the glycolysis enhanced by SV1, we evaluated the
glycolytic activities of ESCC cells after treatment with MIA-
602. Exposure to MIA-602 significantly decreased lactate pro-
duction and glucose uptake of KYSE150 cells, and similar results
were obtained in HKESC-2 cells (P < 0.001 for all) (SI Appendix,
Fig. S3 D and E). Importantly, the overexpression of SV1 further
reversed the decreased glycolysis caused by treatment with MIA-
602 (Fig. 2D). Thus, expression of SV1 in ESCC was induced by
hypoxia and resulted in enhanced glycolysis, which could be
inhibited by GHRH-R antagonists.
SV1 Regulates Glycolytic Metabolism Activity through NF-κB–PFKM
Axis. We further investigated the underlying mechanisms by
which SV1 regulates glycolytic metabolism in ESCC cells. RT-qPCR
was conducted to detect the expression of key enzymes regulating
glycolysis in KYSE140 cells overexpressing SV1. Among the en-
zymes screened, muscle-type phosphofructokinase (PFKM) was
the only one elevated by overexpression of SV1, and similar results
were observed in TE1 cells stably overexpressing SV1 (P < 0.001
for both) (Fig. 3A and SI Appendix, Fig. S4A). Expression of
PFKM in KYSE150 and HKESC-2 cells was obviously decreased
by treatment with MIA-602, as revealed by RT-qPCR and im-
munoblotting analyses (P < 0.01 for Fig. 3B and SI Appendix, Fig.
S4B) (Fig. 3 B and C and SI Appendix, Fig. S4 B and C), indicating
that PFKM is a critical downstream molecule induced by SV1.
Furthermore, the overexpression of SV1 reversed the expression
of PFKM that was suppressed by treatment with MIA-602 (Fig. 3D
and SI Appendix, Fig. S4D). TE1 and KYSE140 cells stably over-
expressing PFKM were subjected to RTCA assays, and in-
creased proliferation was observed in both cells (SI Appendix,
Fig. S4 E–H). Moreover, the lactate production and glucose
uptake that were reduced by MIA-602 could be reversed by
PFKM overexpression (Fig. 3E). These findings collectively
suggest that PFKM is a functional downstream target of SV1 to
regulate glycolytic metabolism.
Fig. 2. Hypoxia-induced SV1 enhances glycolysis. (A) Expression of SV1
measured by RT-qPCR in KYSE140 cells pretreated at normoxia or hypoxia
for 24 h. (B) Schematic of full-length GHRH-R and SV1 structures (DNA,
mRNA, and protein). (C) SV1 expression positively correlates with the gly-
colysis pathway according to a GSEA plot (GSE47404, n = 71). (D) Glucose
uptake and lactate production measured in SV1-overexpressing cells treated
with MIA-602 or vehicle. Error bars indicate SEM. **P < 0.01, ***P < 0.001,
****P < 0.0001 by student’s t test (A) or one-way ANOVA with post hoc
intergroup comparisons (D); n = 3 in each group (A and D).





























We previously demonstrated that nuclear factor kappa B
(NF-κB) mediates the action of GHRH-R antagonists to inhibit
the growth of gastric cancer (14). NF-κB signaling not only par-
ticipates in the progression of ESCC but also stimulates glycolytic
activity (26, 27). Given the facts that NF-κB is a well-known
transcription factor and that we observed alteration of PFKM
transcription in ESCC cells, we wondered if the regulation of
PFKM transcription by SV1 was NF-κB dependent. Bioinformatic
analysis revealed the presence of binding sites for NF-κB p65 in
the PFKM promoter region, suggesting that NF-κB p65 might
regulate the transcription of PFKM (Fig. 4A). Stable cells
expressing p65 or p65 shRNA were established for detecting the
involvement of p65 in glycolytic metabolism regulated by SV1-
PFKM (SI Appendix, Fig. S5 A and B). PFKM transcription in-
creased in p65-overexppressed cells, but decreased in p65-silenced
cells (P < 0.01 for Fig. 4B; P < 0.001 for SI Appendix, Fig. S5C)
(Fig. 4B and SI Appendix, Fig. S5C). Luciferase assay revealed that
forced expression of p65 significantly increased the activity of the
PFKM promoter, whereas knockdown of p65 decreased it (P <
0.01 for both) (Fig. 4C and SI Appendix, Fig. S5D). Next, we
found that p65 could reverse the PFKM promoter activity,
lactate production, and glucose uptake that were decreased by
MIA-602 treatment (Fig. 4 D and E). Immunoblotting analysis
showed that the NF-κB pathway was suppressed by MIA-602
treatment (SI Appendix, Fig. S5E). Moreover, activation of the
canonical NF-κB pathway by stimulation with tumor necrosis
factor alpha (TNF-α) resulted in increased nucleal translocation of
p65 in ESCC cells, whereas MIA-602 treatment dramatically at-
tenuated the translocation of p65 to the nucleus (SI Appendix, Fig.
S5F), demonstrating a strong blocking effect of MIA-602 on the
activation of NF-κB signaling. Further, overexpression of SV1
reversed the suppression of the NF-κB pathway that was conferred
by MIA-602 treatment (Fig. 4F). The nuclear translocation of p65
was blocked by MIA-602, but reappeared after SV1 over-
expression (Fig. 4G). Taken together, these results strongly sup-
port involvement of the NF-κB pathway in glycolytic metabolism
regulated by SV1-PFKM.
MIA-602 Inhibits Tumor Growth by Targeting SV1–NF-κB–PFKM In
Vivo. To demonstrate that GHRH-R antagonists are capable of
inhibiting tumor growth by targeting the SV1-PFKM axis in vivo,
we established xenograft tumor models by subcutaneous (s.c.)
inoculation of KYSE150-SV1, KYSE150-PFKM, and KYSE150-
Vector cells into nude mice (Fig. 5A). As demonstrated by the
tumor growth curves, SV1-overexpressing tumor cells exhibited
enhanced growth (P < 0.0001) (Fig. 5B). Administration of MIA-
602 remarkably inhibited tumor growth in mice bearing KYSE150-
Vector cells (P < 0.001) (Fig. 5B). Of note, both SV1 and PFKM
overexpression partially counteracted the inhibitory effects on tu-
mor growth induced by MIA-602 (Fig. 5B). Corresponding tumor
sizes and weights were obtained on day 28 (Fig. 5C). Importantly,
the effective up-regulation of the mRNA for SV1 and protein
levels in KYSE150-SV1 cells was confirmed in harvested tumors
(P < 0.0001 for Fig. 5D) (Fig. 5 D and E). Inhibition of tumor cell
proliferation by MIA-602 treatment was also reflected by immu-
nohistochemical staining for the proliferation marker Ki67 (Fig.
5F). The down-regulation of the PFKM and NF-κB pathways by
MIA-602 treatment was also demonstrated by immunohisto-
chemistry (Fig. 5F). Thus, MIA-602 inhibits tumor growth medi-
ated by SV1–NF-κB–PFKM signaling in vivo.
Discussion
In this study, we provided experimental and clinical evidence to
demonstrate the significance of the GHRH-R splicing variant
SV1 in the progression and prognosis of ESCC. Both in vitro and
in vivo studies indicate that hypoxia-induced SV1 promotes
ESCC through a previously unknown mechanism that activates
the inflammation-metabolic signaling of NF-κB–PFKM. Our
results document that GHRH-R antagonists exert inhibitory
effects by targeting SV1 in a subgroup of cancers that do not
harbor overexpression of GHRH-R.
The presence of pGHRH-R and its response to GHRH-R
antagonists had been previously demonstrated in various human
cancers, including breast, prostatic, and gastric cancers, and re-
nal cell carcinoma (11, 13, 14, 28). However, there also exist
some tumor types which do not express high levels of pGHRH-R
but which respond to GHRH and GHRH-R antagonists (15–17),
implying that there are alternative targets. The splice variant
SV1 has the greatest structural similarity to pGHRH-R, is widely
expressed by different primary human and experimental cancers,
and is considered the most likely functional splice variant me-
diating the effects of GHRH analogs in tumors (9, 20). ESCC is
one of the most common malignancies of the digestive tract, with
a poor prognosis and a high mortality rate (29–32). By analyzing
a large group of patients and cells, we revealed a very low level of
mRNA for pGHRH-R but a highly enriched SV1 transcript in
ESCC. Furthermore, the significance of SV1 in malignant pro-
gression and clinical outcomes had not been appreciated previously.
By analysis of a patient cohort with follow-up of clinicopathological
Fig. 3. SV1 regulates glycolysis through PFKM. (A) mRNA levels of five key
glycolytic enzymes (HK2, three isoforms of PFK, and PKM) in SV1-overexpressing
KYSE140 cells determined by RT-qPCR. (B and C) Expression of PFKM in
KYSE150 cells treated with MIA-602 for 48 h and analyzed by RT-qPCR (B)
and immunoblotting (C). GAPDH was used as an internal control. (D) Ex-
pression of PFKM in SV1-overexpressing cells treated with MIA-602 or vehicle
and analyzed by immunoblotting. GAPDH was used as an internal control.
(E) Glucose uptake and lactate production measured in PFKM-overexpressing
cells treated with MIA-602 or vehicle. Error bars indicate SEM. N.S., not signifi-
cant; **P < 0.01, ***P < 0.001 by student’s t test (A and B) or one-way ANOVA
with post hoc intergroup comparisons (E); n = 3 in each group (A, B, and E).







































information, the overexpression of SV1 was identified as an in-
dependent prognostic predictor for patients with ESCC. Future
studies are required to confirm these findings across the spectrum
of multiple cohorts in multiple centers. These data predict the
contribution of SV1 to progression of ESCC and emphasize SV1
as a potential therapeutic target in human cancers. Combining
these results with the finding that MIA-602, a highly potent
GHRH-R antagonist, exerts antineoplastic effects in ESCC cells,
we can consider ESCC a representative model to demonstrate
that SV1 mediates the therapeutic effects of GHRH-R antagonists
in human tumors with low expression of pGHRH-R. The expres-
sion of pGHRH-R and SV1, as well as the effects of GHRH-R
antagonists against squamous-cell carcinoma, were previously
largely unknown. Our evidence indicates that SV1 is the main
form of GHRH-R in squamous cell carcinomas that respond to
GHRH-R antagonists (22, 33). Our studies also indicate that in
squamous cell carcinoma SV1 can be used as a therapeutic target
shared with pGHRH-R.
Compared with the canonical full-length GHRH-R, the first
three exons in SV1 are replaced by a fragment of retained intron
3; the rest of the coding region of SV1 is identical with that of
pGHRH-R. The protein product of SV1 differs from the full-
length receptor in a small part of the N-terminal extracellular
domain, which could serve as a proposed signal peptide (18). In
this study, we found that increasing splicing of pGHRH-R into
SV1 was induced by hypoxia in ESCC. Alternative splicing in
tumor cells is one of the cellular adaptations that are largely
promoted by the hypoxic microenvironment in solid tumors.
Given that intron-containing mRNAs are the most frequent
splicing products that result from hypoxia (34–36), it is reason-
able to predict that the enhanced expression of SV1 in ESCC is
induced by hypoxia. We also demonstrated that SV1 in ESCC
cells possesses both ligand-dependent and ligand-independent
functions. Cells transfected with SV1 expression vectors exhibited
a strong induction of cell proliferation, migration, and invasion.
Overexpression of SV1 is sufficient to abrogate suppression of
the NF-κB pathway that was induced by MIA-602 treatment.
This supports the view that SV1 acts as a tumor promoter in-
trinsically in the absence of the ligand GHRH. More importantly,
our results show that SV1 modulates the inflammation-metabolic
signaling of NF-κB–PFKM to sustain high proliferation rates of
tumor cells, implying that isoforms of GHRH-R form a complex
regulatory network in human malignancy. Furthermore, we pro-
vide both in vitro and in vivo data showing that SV1 promotes
tumor growth and that this effect can be reversed by the GHRH-R
antagonist MIA-602, supporting the ligand-dependent and ligand-
independent functions of SV1 (19, 37, 38).
Widespread changes in gene expression, including alterna-
tive splicing of metabolic enzymes, have been implicated in the
process of hypoxia-induced metabolic adaptation of cancer cells
(34, 39, 40). In this study, we defined a previously undocumented
molecular pathway by which hypoxia acts through a splice variant
of a membrane hormone receptor to elevate the glycolytic en-
zyme PFKM, indicating that hypoxia-induced metabolic changes
in cancer cells may involve a more complex regulation. In-
creasing evidence has shown that cancer cells exhibit a metabolic
reprogramming toward aerobic glycolysis to ensure high levels of
energy supply and biomass production to support tumor growth
and progression (41, 42). Hypoxia-induced SV1 triggers a PFKM-
mediated metabolic rewiring, as evidenced by enhanced glucose
consumption and the simultaneously increased production of lac-
tate. Increased glucose flux fuels the proliferation of cancer cells.
Increased lactate secretion is associated with an acidic tumor mi-
croenvironment that contributes to enhanced invasiveness (43, 44).
Fig. 4. Cancer cell glycolysis regulated by SV1-PFKM is NF-κB dependent. (A) Graphic representation of the four putative NF-κB p65 binding sites in the PFKM
proximal promoter. (B) mRNA level of PFKM in p65-overexpressing cells determined by RT-qPCR. (C) The PFKM luciferase reporter was transfected into
KYSE140-p65 cells and control vector cells, and the relative PFKM promoter activities were measured based on the luciferase activities. (D and E) Relative
PFKM promoter activities (D), glucose uptake, and lactate production (E) measured in p65-overexpressing cells treated with MIA-602 or vehicle. (F) SV1-
overexpressing cells treated with MIA-602 or vehicle before being harvested for immunoblot analyses of the labeled antigens. GAPDH was used as an internal
control. (G) Subcellular localization of p65 (red) in KYSE150 cells as analyzed by immunofluorescence assay. Nuclei stained with DAPI (blue). Error bars indicate
SEM. **P < 0.01, ***P < 0.001 by student’s t test (B and C) or one-way ANOVA with post hoc intergroup comparisons (D and E); n = 3 in each group (B–E).
(Scale bars, 10 μm.)





























Our findings illustrate that SV1 promotes growth and metastasis
of cancer through the induction of PFKM and aberrant glycolytic
metabolism.
PFKM is one of the isozymes encoded by phosphofructokinase-1
(PFK-1), which catalyzes the second irreversible step in the
glycolytic pathway by phosphorylating fructose-6-phosphate to
form fructose-1, 6-bisphosphate (45, 46). It is the key regulatory
enzyme mediating changes in glycolysis in cancer cells (45, 46).
However, the importance of PFKM and its upstream regulators
in tumorigenic progression remains largely unknown. We found
that SV1 up-regulates PFKM in an NF-κB–dependent manner,
supporting the view that SV1 is a key regulator and that NF-κB is
a previously unrecognized transcription activator of PFKM.
Glycolytic inhibitors, including pharmaceuticals that directly in-
hibit PFK-1, have been considered for cancer treatment. One
major challenge of these inhibitors is their potential toxicity to
certain normal tissues that also use glucose as their main energy
source, such as brain, retinae, and testis (47). Interestingly, MIA-
602 effectively decreased PFKM in both ESCC cells and ESCC-
bearing mice. Given that the side effects of GHRH analogs are
minimal (9, 48), we propose that GHRH-R antagonists might be
more practically used as glycolytic inhibitors to treat cancers.
However, this finding needs to be validated clinically.
In summary, these studies addressed a long-standing question,
which is why subgroups of cancers with low expression of pGHRH-R
respond to GHRH-R antagonists, establishing the role of SV1 as
a hypoxia-driven spliced tumor promoter and as a mediator
linking hypoxia and glycolysis in cancer. MIA-602 counteracts
NF-κB–PFKM signaling suppressing aberrant glycolytic metab-
olism and tumor progression in vitro and in vivo by inhibiting
SV1. SV1 is highlighted as a therapeutic target of GHRH-R
antagonists in cancer. Demonstration of the importance of
SV1 may shed light on how to select the appropriate patients
with cancers which do not harbor GHRH-R overexpression for
the use of GHRH-R antagonists.
Materials and Methods
Clinical Patients and Samples. All specimens of primary ESCC, along with
adjacent noncancerous tissues, were from patients who had undergone
radical surgery without preoperative therapy at the Cancer Hospital of
Shantou University Medical College (CHSUMC) during 2011–2012. All samples
were histopathologically and clinically confirmed as ESCC. Fifty-eight surgi-
cal samples of ESCC were freshly collected by snap-freezing in liquid nitro-
gen in a tumor-banking protocol, and were used for RNA extraction and
RT-qPCR analysis. All clinical research protocols of this study were reviewed and
approved by the Ethics Committee of Shantou University Medical College.
Written informed consent was obtained from patients in accordance with the
Declaration of Helsinki.
Peptides and Chemicals. GHRH-R antagonist MIA-602 was synthesized in the
laboratory of A.V.S in Miami. For in vitro experiments, the peptides were
dissolved in dimethyl sulfoxide (DMSO) to form a 5-mM solution, and
further diluted with cell culture medium to the concentration indicated.
The final concentration of DMSO in the culture medium was 0.1% (vol/vol).
For the in vivo study, animals were treated daily by s.c. administration of
Fig. 5. MIA-602 suppresses SV1-mediated ESCC tumor growth in vivo. (A) Scheme indicating the timing of xenografting and longitudinal treatment. (B)
Tumor growth curves of KYSE150-SV1 and KYSE150-PFKM cells treated with MIA-602 or vehicle. (C) Tumors harvested on day 28 (Left) and average weights of
tumors (Right). (D and E) Expression of SV1 detected by RT-qPCR (D) and immunoblotting (E) in tumor tissues from mice bearing KYSE150-SV1 or KYSE150-
Vector cells. GAPDH was used as an internal control. (F) Representative images of immunohistochemistry of Ki67, PFKM, and p-p65 in tumor sections derived
from mice (Top). Plots of percentages or mean of integrated optical density (IOD) of five groups of cells expressing the indicated proteins (Bottom). Error bars
indicate SEM. N.S., not significant; **P < 0.01, ***P < 0.001, ****P < 0.0001 by one-way ANOVA with post hoc intergroup comparisons; n = 10 in each group.
(Scale bars, 50 μm.)







































5 μg GHRH-R antagonist MIA-602 or vehicle solutions (0.1% DMSO in 5.5%
mannitol; Sigma).
Tumor Xenografts. A total of 5 × 105 KYSE150 cells was resuspended in 100 μL
phosphate-buffered saline (PBS) and injected s.c. into the flanks of 6-wk-old
female nude mice (Vital River Laboratory Animal Technology Co.). Animal
experiments were reviewed and approved by the Ethics Committee of
Shantou University Medical College.
Additional materials and methods are described in SI Appendix, Materials
and Methods.
Data Availability Statement.All data discussed in the paper are available in the
manuscript or SI Appendix.
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